ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Glomerular Diseases: 2025 Update

Glomerular Diseases: 2025 Update

November 05, 2025 | 07:00 AM - 06:00 PM

Location: Room TBD1, Convention Center

Session Description

Glomerular medicine is exploding with exciting new understanding of disease pathogenesis, which has led to developments in novel genetic and serological diagnostic tools, clinical trials, and potential new treatments. In this program, a panel of experts discusses these advances in the form of comprehensive updates and case-based discussions (adult and pediatric) with time for audience questions.

This program explores novel changes in our favorites: IgA nephropathy, lupus nephritis, podocytopathies (FSGS/minimal change disease [MCD]), ANCA-associated vasculitis, membranous glomerulonephritis, complement in kidney disease, and monoclonal gammopathies of renal significance. Hot topics are also addressed, including how and when to use genetics in the diagnosis and treatment of glomerular diseases, type IV collagen-related diseases, and anticipated uses of artificial intelligence (AI) in the diagnosis of glomerular diseases. Participants learn about cutting-edge clinical applications in treatment, pathology, and genetics that continue to change the diagnostic and therapeutic landscape in glomerular medicine.

Session Objectives

Upon completion of this program, the participant will be able to: 1) describe and integrate pathophysiology, pathology, diagnostics, and therapeutic options for glomerular diseases; 2) summarize information from current basic and clinical research studies and its application to the diagnosis and management of glomerular diseases; 3) analyze nuances in the treatment of patients with difficult-to-manage glomerular diseases; and 4) discuss when to use novel medications and/or to enroll patients in clinical trials as medical therapy options.

Learning Pathway(s)

  • Glomerular Diseases

Moderators

Presentations